Supplement Table 1: Baseline description of PROSa participants.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Value** | **Stratification** | **All  N=1309  N (%)/ median (IQR)** | **Soft Tissue Sarcoma  N=910 (69.7%)  N (%)/ median (IQR)** | **Bone Sarcoma N= 236 (18.1%)  N (%)/ median (IQR)** | **GIST N= 159 (12.2%)  N (%)/ median (IQR)** |
| Sex | female |  | 624 (47.7) | 435 (47.8) | 105 (44.5) | 84 (52.8) |
| male |  | 681 (52.2) | 475 (52.2) | 131 (55.5) | 75 (47.2) |
| Age at diagnosis |  |  | 54.1 (41.8; 64.2) | 55.8 (46.5; 65.5) | 36.2 (22.0; 53.7) | 58.3 (49.4; 66.6) |
| Time since diagnosis |  |  | 2.3 (0.7; 5.9) | 2.1 (0.6; 5.2) | 2.8 (1.1; 6.6) | 3.5 (0.9; 9.5) |
| 0-<0.5 years |  | 261 (20.0) | 200 (22.0) | 34 (14.4) | 27 (17.0) |
| 0.5-<1 year |  | 138 (10.6) | 100 (11.0) | 21 (8.9) | 17 (10.7) |
| 1-<2 years |  | 188 (14.4) | 141 (15.5) | 35 (14.8) | 12 (7.5) |
| 2-<5 years |  | 341 (26.1) | 234 (27.7) | 70 (29.7) | 37 (23.3) |
| more than 5 years |  | 377 (28.9) | 235 (25.8) | 76 (32.2) | 66 (41.5) |
| Year of Diagnose | 2018 |  | 277 (21.2) | / | / | / |
| 2017 |  | 241 (18.4) | / | / | / |
| 2016 |  | 177 (13.5) | / | / | / |
| all other |  | 614 (46.9) | / | / | / |
| Sarcoma type | liposarcoma |  | 240 (18.4) | 240 (26.4) | / | / |
| unclassified sarcoma |  | 194 (14.9) | 186 (20.4) | 8 (3.4) | / |
| fibroblastic, myofibroblastic, fibrohistiocytic sarcoma |  | 153 (11.7) | 147 (16.2) | 6 (2.5) | / |
| leiomyosarcoma |  | 150 (11.5) | 148 (16.3) | 2 (0.8) | / |
| osteosarcoma |  | 87 (6.7) | 4 (0.4) | 83 (35.2) | / |
| chondrosarcoma |  | 75 (5.7) | 13 (1.4) | 62 (26.3) | / |
| Ewing sarcoma |  | 56 (4.3) | 12 (1.3) | 44 (18.6) | / |
| synovialsarcoma |  | 53 (5.8) | 53 (4.1) | / | / |
| bone sarcoma -other |  | 30 (2.3) | / | 30 (12.7) | / |
| vascular tumor |  | 30 (2.3) | 29 (3.2) | 1 (0.4) | / |
| nerve sheath tumor |  | 21 (1.6) | 21 (2.3) | / | / |
| stromasarcoma |  | 19 (1.5) | 19 (2.1) | / | / |
| tumor of uncertain differentiation – other |  | 19 (1.5) | 19 (2.1) | / | / |
| skeletal-muscle tumor |  | 19 (1.5) | 19 (2.1) | / | / |
| GIST |  | 159 (12.2) | / | / | 159 (100) |
| Site | trunk |  | 629 (48.2) | 447 (49.1) | 23 (9.7) | 159 (100) |
| abdomen | / | 81 (8.9) | / | / |
| retroperitoneum | / | 116 (12.7) | / | / |
| thorax | / | 96 (10.5) | 14 (5.9) | / |
| pelvis | / | 154 (16.9) | / | / |
| spine | / | / | 9 (3.8) | / |
| stomach | / | / | / | 69 (43.4) |
| small bowel | / | / | / | 47 (29.6) |
| GIST - other | / | / | / | 43 (27) |
| limbs |  | 610 (46.7) | 406 (44.6) | 204 (86.4) | / |
| lower limbs | / | 334 (36.7) | 128 (54.2) | / |
| upper limbs | / | 72 (7.9) | 33 (14.0) | / |
| pelvis | / | / | 43 (18.2) | / |
| somewhere else |  | 66 (5.1) | 57 (6.3) | 9 (3.8) | / |
| back | / | 27 (3.0) | / | / |
| head/ neck | / | 24 (2.6) | 9 (3.8) | / |
| unknown | / | 6 (0.7) | / | / |
| Grading | low grade |  | 158 (12.1) | 140 (15.4) | 18 (7.6) | / |
| high grade |  | 705 (53.9) | 548 (60.4) | 157 (66.5) | / |
| not accessible |  | 6 (0.5) | 6 (0.7) | 0 | / |
| unknown |  | 66 (5.1) | 55 (90.2) | 6 (2.5) | / |
| not graded | locally aggressive + rarely metastatic | 108 (8.3) | 71 (7.8) | 37 (15.7) | / |
| GIST | 159 (12.1) | / | / | 159 (100) |
| no surgery | 19 (1.5) | 17 (1.9) | 2 (0.8) | / |
| neoadjuvant therapy | 26 (2.0) | 20 (2.2) | 5 (2.1) | / |
| grading not usual\* | 62 (4.8) | 51 (5.6) | 11 (4.7) | / |
| T-Stage | T1 |  | 186 (14.3) | 121 (13.3) | 60 (25.4) | 5 (3.1) |
| T2-T4 |  | 589 (45.1) | 417 (45.8) | 77 (32.6) | 95 (59.7) |
| STS T2 (7.ed)/ T2-T4 (8.ed) | / | 417 (45.8) | / | / |
| BS T2 | / | / | 72 (30.5) | / |
| BS T3 | / | / | 5 (2.1) | / |
| GIST T2 | / | / | / | 28 (17.6) |
| GIST T3 | / | / | / | 53 (33.3) |
| GIST T4 | / | / | / | 14 (8.8) |
| Tx |  | 14 (1.1) | 9 (1.0) | 2 (0.8) | 3 (1.9) |
| tumor not TNM classified\*\* |  | 31 (2.4) | 30 (3.3) | 1 (0.4) | / |
| locally aggressive + rarely metastatic |  | 108 (8.3) | 71 (7.8) | 37 (15.7) | / |
| uterine leiomyosarcoma or endometrial stromasarcoma |  | 40 (3.1) | 40 (4.4) | / | / |
| T1 | / | 17 (1.9) | / | / |
| T2 | / | 10 (1.1) | / | / |
| T3 | / | 2 (0.2) | / | / |
| T4 | / | 0 | / | / |
| unknown | / | 11 (1.2) | / | / |
| unknown |  | 341 (26.1) | 222 (24.4) | 59 (18.7) | 56 (35.2) |
| Tumor depth | superficial |  | / | 76 (8.4) | / | / |
| deep |  | / | 572 (62.9) | / | / |
| not applicable |  | / | 18 (2.0) | / | / |
| locally aggressive + rarely metastatic |  | / | 71 (7.8) | / | / |
| unknown |  | / | 173 (19.0) | / | / |
| Malignancy of tumor | locally aggressive + rarely metastatic |  | 108 (8.3) | 71 (7.8) | 37 (15.7) | / |
| malignant |  | 1197 (91.7) | 839 (92.2) | 199 (84.3) | 159 (100) |
| Metastasis | at diagnosis | no | 928 (71.4) | 652 (72.0) | 174 (73.7) | 102 (64.6) |
| yes | 133 (10.2) | 81 (9.0) | 18 (7.6) | 34 (21.5) |
| unknown | 238 (18.3) | 172 (19.0) | 44 (18.6) | 22 (13.9) |
| after diagnosis | no | 899 (68.9) | 625 (68.7) | 177 (75.0) | 97 (61.0) |
| yes | 355 (27.2) | 247 (27.1) | 48 (20.3) | 60 (37.7) |
| suspicion | 23 (1.8) | 18 (2.0) | 4 (1.7) | 1 (0.6) |
| unknown | 28 (2.1) | 20 (2.2) | 7 (3.0) | 1 (0.6) |
| until baseline | no | 719 (55.3) | 498 (55.0) | 146 (61.9) | 75 (47.5) |
| yes | 428 (32.9) | 299 (33.0) | 60 (25.4) | 69 (43.7) |
| unknown | 153 (11.8) | 109 (12.0) | 30 (12.7) | 14 (8.9) |
| Tumor recurrence | no recurrence |  | 947 (72.6) | 636 (69.9) | 190 (80.5) | 121 (76.1) |
| recurrence |  | 324 (24.8) | 252 (27.7) | 37 (15.7) | 35 (22.0) |
| suspicion |  | 13 (1.0) | 8 (0.9) | 3 (1.3) | 2 (1.3) |
| unknown |  | 21 (1.6) | 14 (1.5) | 6 (2.5) | 1 (0.6) |
| Treatment intention | curative |  | 964 (73.9) | 664 (73.0) | 204 (86.4) | 96 (60.4) |
| palliative |  | 311 (23.8) | 225 (24.8) | 25 (10.6) | 61 (38.4) |
| unknown |  | 29 (2.2) | 20 (2.2) | 7 (3.0) | 2 (1.3) |
| Disease status | complete remission |  | 579 (44.4) | 376 (41.3) | 157 (66.5) | 46 (28.9) |
| partial remission/ stable disease |  | 379 (29.0) | 266 (29.2) | 36 (15.3) | 77 (48.8) |
| progress |  | 194 (14.9) | 153 (16.8) | 22 (9.3) | 19 (11.9) |
| unknown |  | 153 (11.7) | 115 (12.6) | 21 (8.9) | 17 (10.7) |
| Treatment status | in treatment |  | 418 (32.1) | 269 (29.6) | 63 (26.8) | 86 (54.1) |
| not in treatment |  | 878 (67.3) | 635 (72.3) | 171 (72.8) | 72 (45.3) |
|  | aftercare | 728 (55.8) | 505 (55.5) | 161 (68.2) | 62 (39.0) |
|  | treatment pause | 8 (0.6) | 8 (0.9) | 0 | 0 |
|  | treatment in planning | 143 (11.0) | 122 (13.4) | 11 (4.7) | 10 (6.3) |
| unknown |  | 8 (0.6) | 6 (0.7) | 1 (0.4) | 1 (0.6) |
| Surgery | no |  | 158 (12.1) | 116 (12.7) | 20 (8.5) | 22 (13.8) |
| yes |  | 1137 (87.2) | 791 (86.9) | 212 (90.2) | 134 (84.3) |
|  | 1 | 783 (60.0) | 492 (54.1) | 176 (74.6) | 115 (72.3) |
|  | 2 | 246 (18.9) | 210 (23.1) | 23 (9.7) | 13 (8.2) |
|  | >2 | 108 (8.3) | 89 (9.8) | 13 (5.5) | 6 (3.8) |
| unknown |  | 10 (0.8) | 3 (0.3) | 4 (1.7) | 3 (1.9) |
| Chemotherapy | no |  | 686 (52.6) | 472 (51.9) | 89 (37.7) | 125 (78.6) |
| yes |  | 602 (46.2) | 426 (46.9) | 143 (60.6) | 33 (20.8) |
| unknown |  | 16 (1.2) | 11 (1.2) | 4 (1.7) | 1 (0.6) |
| Radiotherapy | no |  | 775 (59.4) | 442 (48.6) | 183 (77.5) | 150 (94.3) |
|  | yes |  | 498 (38.2) | 445 (48.9) | 46 (19.5) | 7 (4.4) |
|  | unknown |  | 32 (2.5) | 23 (2.5) | 7 (3.0) | 2 (1.3) |
| TKI | no |  | 1055 (80.8) | 795 (87.4) | 222 (94.1) | 38 (23.9) |
|  | yes |  | 202 (15.5) | 75 (8.2) | 6 (2.5) | 121 (76.1) |
|  | unknown |  | 48 (3.7) | 40 (4.4) | 8 (3.4) | 0 |
| Hyperthermia | no |  | / | 831 (91.3) | / | / |
|  | yes |  | / | 52 (5.7) | / | / |
|  | unknown |  | / | 27 (3.0) | / | / |
| ILP | no |  | / | 857 (94.2) | / | / |
|  | yes |  | / | 22 (2.4) | / | / |
|  | unknown |  | / | 31 (3.4) | / | / |
| Treatments combined | surgery only |  | 350 (26.9) | 246 (27.1) | 73 (31.5) | 31 (19.5) |
| surgery + ST |  | 334 (25.7) | 137 (15.1) | 100 (43.1) | 97 (61.0) |
| CT | 255 (21.9) | 131 (14.4) | 99 (42.6) | 25 (15.7) |
| TKI | 124 (9.5) | 28 (3.2) | 2 (0.9) | 94 (59.1) |
| surgery + RT |  | 191 (14.7) | 182 (20.0) | 9 (4.7) | 0 |
| surgery + ST + RT |  | 262 (20.2) | 226 (24.9) | 30 (12.9) | 6 (2.3) |
| CT | 248 (19.1) | 218 (24.0) | 28 (12.0) | 2 (1.2) |
| TKI | 47 (3.6) | 39 (4.3) | 3 (1.3) | 5 (3.1) |
| ST only |  | 82 (6.3) | 51 (5.6) | 10 (4.3) | 21 (13.2) |
|  | CT | 65 (5.0) | 50 (5.5) | 10 (4.3) | 5 (3.1) |
|  | TKI | 26 (2.0) | 4 (0.4) | 1 (0.4) | 21 (13.1) |
| RT only |  | 10 (1.1) | 1 (0.4) | 0 | 11 (0.8) |
| ST + RT |  | 34 (2.6) | 27 (3.0) | 6 (2.6) | 1 (0.4) |
| CT | 34 (2.6) | 27 (3.0) | 6 (2.6) | 1 (0.4) |
| TKI | 4 (0.3) | 3 (0.3) | 0 | 1 (0.6) |
| no therapy (yet) |  | 33 (2.5) | 29 (3.2) | 1 (0.4) | 3 (1.9) |
| other therapy |  | 2 (0.2) | 0 | 2 (0.9) | 0 |

IQR= interquartile range; TKI= tyrosine kinase inhibitor; ILP= isolated limb perfusion; ST= systemic therapy; RT= radio therapy; CT= chemotherapy. \* Usually not graded applies to: solitary fibrous tumor, dermatofibrosarcoma protuberans, GIST, epithelioid hemangioendothelioma, intima sarcoma, clear cell sarcoma, alveolar soft tissue sarcoma, chordoma, angiosarcoma, rhabdomyosarcoma. \*\*No TNM applies to: angiosarcoma, Kaposi sarcoma, dermatofibrosarcoma protuberans.